You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Optimization of small molecule triazine antituberculars for in vivo efficacy

    SBC: COLLABORATIONS PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is due to infection with the pathogen Mycobacterium tuberculosis Mtb This disease represents a global health pandemic as based on WHO statistics it claims the lives of approximately million people per year while infecting nearly million New drugs are urgently needed with novel mechanisms of action that treat this disease while also ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes

    SBC: Jenesis Biosciences LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A Bullet Proof vascular graft to prevent dialysis access cannulation injury

    SBC: Innavasc Medical, Inc.            Topic: 400

    Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Alkontrol herbal for Treating Alcohol Abuse

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A smart needle guide template for MRI-guided transperineal prostate biopsy

    SBC: Physical Sciences Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Physical Sciences Inc. (PSI) and the Surgical Navigation and Robotics Laboratory (SNR) at Brigham and Women's Hospital (BWH) propose to develop and test a Smart Template to guide transperineal targeted prostate biopsiesand subsequent therapy under magnetic resonance imaging (MRI). The project aims to solve the problem of poor diagnostic yield in prostate b ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. POC 2-D Diffusion Assay for self-monitoring of BNP

    SBC: SENTILUS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this STTR proposal is to develop a 2-D diffusion point-of-care assay (POC) for B-type natriuretic peptide (BNP). The primary goal of the proposed work is to create a test format that will allow patientswith chronic heart failure to quantitatively self-monitor serum levels of BNP. Determination of baseline level of BNP and changes in this level ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Novel immunotherapy strategy for treatment of pancreatic cancer

    SBC: Oncotab, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Atrial fibrillation remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality. Cryotherapy and radiofrequency catheter ablations for the purpose of eliminating atrial fibrillation have become a mainstream treatment option. They produce lesions that block the spread of elect ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A novel therapeutic approach for Acute Lung Injury/ARDS

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government